Stryker Corporation $SYK Stock Position Reduced by Raiffeisen Bank International AG

Raiffeisen Bank International AG lessened its stake in Stryker Corporation (NYSE:SYK) by 8.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 93,268 shares of the medical technology company’s stock after selling 8,678 shares during the quarter. Raiffeisen Bank International AG’s holdings in Stryker were worth $30,827,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of SYK. Gables Capital Management Inc. purchased a new position in shares of Stryker during the 2nd quarter valued at $25,000. Kilter Group LLC purchased a new position in Stryker in the second quarter valued at about $25,000. Godfrey Financial Associates Inc. purchased a new position in Stryker in the fourth quarter valued at about $26,000. Sankala Group LLC acquired a new position in Stryker in the 4th quarter worth about $26,000. Finally, Compass Financial Management LLC purchased a new stake in shares of Stryker during the 2nd quarter worth about $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Down 1.3%

Shares of SYK stock opened at $308.07 on Friday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The company has a market cap of $118.17 billion, a PE ratio of 31.92, a price-to-earnings-growth ratio of 1.95 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $329.43 and its two-hundred day moving average is $329.92.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the prior year, the firm earned $3.13 EPS. Stryker’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts predict that Stryker Corporation will post 15.03 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is presently 36.48%.

Insider Transactions at Stryker

In related news, insider Debra King sold 826 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. This trade represents a 6.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 351,267 shares of company stock worth $118,197,701. Company insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Leerink Partners lowered their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Royal Bank Of Canada reduced their target price on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Piper Sandler decreased their target price on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Raymond James Financial set a $370.00 price target on shares of Stryker in a report on Friday, July 31st. Finally, Truist Financial lifted their price objective on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.